Cooper D S, Steigerwalt S, Migdal S
Arch Intern Med. 1987 Apr;147(4):785-6.
The simultaneous occurrence of thyrotoxicosis and renal failure has rarely been reported in the literature, and data concerning appropriate antithyroid drug management in this circumstance are limited. We studied propylthiouracil pharmacokinetics in one such patient basally and while the patient was receiving hemodialysis. On a day when the patient was not receiving hemodialysis, propylthiouracil serum levels were high, but serum propylthiouracil half-life was not prolonged. During hemodialysis, serum propylthiouracil levels were normal, and the time to peak serum levels was delayed; the disappearance of the drug from the serum was normal after hemodialysis was completed. The amount of propylthiouracil that appeared in the dialysate was approximately 5% of the administered dose. These data suggest that propylthiouracil can be administered in standard dosages to patients with thyrotoxicosis and renal failure.
甲状腺毒症与肾衰竭同时出现的情况在文献中鲜有报道，关于在此种情况下合适的抗甲状腺药物管理的数据也很有限。我们对一名此类患者在基础状态下以及接受血液透析时的丙硫氧嘧啶药代动力学进行了研究。在患者未接受血液透析的一天，丙硫氧嘧啶血清水平较高，但血清丙硫氧嘧啶半衰期未延长。在血液透析期间，血清丙硫氧嘧啶水平正常，血清水平达峰时间延迟；血液透析结束后药物从血清中的消失情况正常。出现在透析液中的丙硫氧嘧啶量约为给药剂量的5%。这些数据表明，丙硫氧嘧啶可按标准剂量给予甲状腺毒症合并肾衰竭的患者。
